|
Session 10
Oral Abstracts
New Antiretrovirals and Clinical Trials
Monday, 10 am-12 noon
Room: Auditorium |
| 10:00 am 34 |
Structure of HIV-1 CAN in Complex with CAP-1, an Assembly Inhibitor
Brian Kelly*1, S Kyere2, I Kinde2, C Tang2, B Howard3, H Robinson4, W Sundquist1, M Summers2, and C Hill1
1Univ of Utah, Salt Lake City, US; 2Univ of Maryland, Baltimore, US; 3Southern Utah Univ, Cedar City, US; and 4Brookhaven Natl Lab, Upton, NY, US |
| 10:15 am 35 |
A Prospective, Randomized, Controlled, Open-label Trial Evaluating the Effect of Therapeutic Drug Monitoring and Protease Inhibitor Dose Escalation on Viral Load Responses in Antiretroviral-experienced, HIV-infected Patients with a Normalized Inhibitory Quotient
Lisa Demeter*1, H Jiang2, L Mukherjee2, G Morse3, R DiFrancesco3, K Klingman4, L Bacheler5, R DiCenzo3, A Rinehart6, M Albrecht7, and the A5146 Study Team
1Univ of Rochester Sch of Med Dentistry, NY, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3State Univ of New York at Buffalo, US; 4Div of AIDS, NIH, Bethesda, MD, US; 5VircoLab Inc, Durham, NC, US; 6Tibotec Therapeutics, Bridgewater, NJ, US; and 7Beth Israel Deaconess Med Ctr, Boston, MA, US |
| 10:30 am 36 |
Re-initiation of ART in the CD4-guided ART Interruption Group in the SMART Study Lowers Risk of Opportunistic Disease or Death
Wafaa El-Sadr and SMART Study Group
Harlem Hosp Ctr and Columbia Univ, New York, NY, US |
| 10:45 am 37 |
Efficacy and Safety of Once-daily Atazanavir/Ritonavir Compared to Twice-daily Lopinavir/Ritonavir, Each in Combination with Tenofovir and Emtricitabinein ARV-naive HIV-1-infected Subjects: The CASTLE Study, 48-week Results
Jean-Michel Molina*1, J Andrade-Villanueva2, J Echevarria3, P Chetchotisakd4, J Corral5, N David6, M Mancini7, L Percival7, A Thiry7, and D McGrath7
1Hosp St Louis, Paris, France; 2Hosp Civil de Guadalajara, Mexico; 3Hosp Natl Cayetano Heredia, Lima, Peru; 4Khonkaen Univ, Thailand; 5Hosp Intl Gral de Agudos Oscar Alende, Buenos Aires, Argentina; 6Brooklyn Med Ctr, Western Cape, South Africa; and 7Bristol-Myers Squibb R&D, Wallingford, CT, US |
| 11:00 am 38 |
Safety and Activity of SCH532706, a Small Molecule Chemokine Receptor 5 Antagonist in HIV-1-infected Individuals
Sarah Pett*1, S Emery1, K MacRae2, R Norris2, M McCarthy3, A Tendlokar3, J Tseng3, K Williams4, and D Cooper1
1Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, Australia; 2St Vincent`s Hosp, Sydney, Australia; 3Schering-Plough Res Inst, Kenilworth, NJ, US; and 4Clinical Trials Ctr, St Vincent`s Hosp, Sydney, Australia |
| 11:15 am 39LB |
Vicriviroc, a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral Replication in Treatment-experienced Adults: VICTOR-E1 48-week Results
Barry Zingman*1, J Suleiman2, E DeJesus3, J Slim4, M McCarthy5, E Lee5, N Case5, C Mak5, and L Dunkle5
1Montefiore Med Ctr, Bronx, NY, US; 2Brazilmed Assistencia Medica e Pesquisa, Sao Paolo; 3Orlando Immunology Ctr, FL, US; 4St Michael`s Med Ctr, Newark, NJ, US; and 5Schering-Plough Res Inst, Kenilworth, NJ, US |
| 11:30 am 40LB |
Virological Correlates Associated with Treatment Failure at Week 48 in the Phase 3 Study of Maraviroc in Treatment-naive Patients
J Heera1, M Saag2, P Ive3, J Whitcomb4, M Lewis5, L McFadyen5, J Goodrich1, H Mayer1, E van der Ryst5, and Mike Westby*5
1Pfizer Global R&D, New London, CT, US; 2Univ of Alabama at Birmingham, US; 3Univ of the Witwatersrand, Johannesburg, South Africa; 4Monogram Biosci, South San Francisco, CA, US; and 5Pfizer Global R&D, Sandwich, UK |
| 11:45 am 41 |
Trends in Second Virologic Failure and Predictors of Subsequent Mortality among ART-experienced Patients: North American Experience
Stephen Deeks and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA
Univ of California, San Francisco, US |
|
